Claims
- 1. A compound selected from the group consisting of:
- (A) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -(diphenylacetyl)-argininamide;
- (B) (R,S)-N.sup.5 -(aminoiminomethyl)-N.sup.2 -(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-N.sup.5 -methyl-ornithinamide;
- (C) (R)-N-[[4-(aminocarbonylmethyl)phenyl]methyl]-N.sup.2 -(diphenylacetyl)-argininamide;
- (D) (R)-N.sup.2 -(diphenylacetyl)-N-[[4-(methylaminocarbonylaminomethyl)phenyl]methyl]-argininamide;
- (E) (R)-N.sup.2 -(diphenylacetyl)-N-[[4-(ethylaminocarbonylaminomethyl)phenyl]methyl]-argininamide;
- (F) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-(4-methoxyphenyl)acetyl]-argininamide;
- (G) (R)-N.sup.2 -(diphenylacetyl)-N-[[4-(ethoxycarbonylmethylaminocarbonylaminomethyl)phenyl]methyl]-argininamide;
- (H) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-(4-fluorophenyl)acetyl]-argininamide;
- (I) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-(4-chlorophenyl)acetyl]-argininamide;
- (J) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-(4-hydroxyphenyl)acetyl]-argininamide;
- (K) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-[4-(methoxycarbonylmethoxy)phenyl]acetyl]-argininamide; and,
- (L) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-[4-(hydroxycarbonylmethoxy)phenyl]acetyl]-argininamide;
- or a pharmaceutically acceptable salt thereof.
- 2. A compound selected from the group consisting of:
- (A) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -(diphenylacetyl)-argininamide;
- (B) (R,S)-N.sup.5 -(aminoiminomethyl)-N.sup.2 -(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-N.sup.5 -methyl-ornithinamide;
- (C) (R)-N-[[4-(aminocarbonylmethyl)phenyl]methyl]-N.sup.2 -(diphenylacetyl)-argininamide;
- (D) (R)-N.sup.2 -(diphenylacetyl)-N-[[4-(ethoxycarbonylmethylaminocarbonylaminomethyl)phenyl]methyl]-argininamide;
- (E) (R)-N-[[.sup.4 -(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-(4-fluorophenyl)acetyl]-argininamide;
- (F) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-(4-chlorophenyl)acetyl]-argininamide;
- (G) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-(4-hydroxyphenyl)acetyl]-argininamide; and,
- (H) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-[4-(hydroxycarbonylmethoxy)phenyl]acetyl]-argininamide;
- or a pharmaceutically acceptable salt thereof.
- 3. A compound selected from the group consisting of:
- (A) (R)-N.sup.2 -(diphenylacetyl)-N-[[4-(methylaminocarbonylaminomethyl)phenyl]methyl]-argininamide;
- (B) (R)-N.sup.2 -(diphenylacetyl)-N-[[4-(ethylaminocarbonylaminomethyl)phenyl]methyl]-argininamide;
- (C) (R)-N.sup.2 -(diphenylacetyl)-N-[[4-(ethoxycarbonylmethylaminocarbonylaminomethyl)phenyl]methyl]-argininamide;
- (D) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-[4-(methoxycarbonylmethoxy)phenyl]acetyl]-argininamide; and,
- (E) (R)-N-[[4-(aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -[bis-[4-(hydroxycarbonylmethoxy)phenyl]acetyl]-argininamide;
- or a pharmaceutically acceptable salt thereof.
- 4. A pharmaceutical composition comprising a compound according to claim 1, 2 or 3, or a pharmaceutically acceptable salt thereof.
- 5. A method for treating a disease in which the Y1 receptor subtype is involved, which method comprises administering to a host in need of such treatment a therapeutically effective amount of a compound in accordance with claim 1, 2 or 3, or a pharmaceutically acceptable salt thereof.
- 6. A method for treating a disorder or disease associated with the inhibition of the Y1 receptor subtype, which method comprises administering to a host in need of such treatment a therapeutically effective amount of a compound in accordance with claim 1, 2 or 3, or a pharmaceutically acceptable salt thereof.
- 7. A method for treating obesity, bulimia nervosa, diabetes or dyslipidemia, which method comprises administering to a host in need of such treatment a therapeutically effective amount of a compound in accordance with claim 1, 2 or 3, or a pharmaceutically acceptable salt thereof.
- 8. A method for treating obesity, which method comprises administering to a host in need of such treatment a therapeutically effective amount of a compound in accordance with claim 1, 2 or 3, or a pharmaceutically acceptable salt thereof.
- 9. A method for treating memory loss, migraine, sleep disorders, pain, cardiovascular diseases, subarachnoidal bleeding, vascular-hypertrophic changes, cerebral and coronary vasospasms, chronic kidney failure, hyperthyroidism, epileptic diseases or tumor diseases, which method comprises administering to a host in need of such treatment a therapeutically effective amount of a compound in accordance with claim 1, 2 or 3, or a pharmaceutically acceptable salt thereof.
- 10. A method for treating hypertension, which method comprises administering to a host in need of such treatment a therapeutically effective amount of a compound in accordance with claim 1, 2 or 3, or a pharmaceutically acceptable salt thereof.
RELATED APPLICATIONS
This application is a continuation-in-part of Ser. No. 08/945,048, filed Feb. 10, 1998, now abandoned, which is a International Application Number PCT/EP96/05222 filed Oct. 14, 1996.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5616620 |
Rudolf et al. |
Apr 1997 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
4301452 |
Jul 1994 |
DEX |
WO 94 17035 |
Aug 1994 |
WOX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
945048 |
|
|